Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab

Margiotta, Flavia Manzo; Michelucci, Alessandra; Panduri, Salvatore; Tonini, Annalisa; Davini, Giulia; Romanelli, Marco; Morganti, Riccardo; Dini, Valentina

doi:10.1111/jdv.17944

Cited by 3 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Clinical practice provides evidence that biologic drug switches are frequent and literature data about clinical risk factors for these therapeutic adjustments and overall drug discontinuation are becoming available. 39,40 Therapy switches clearly affect the health sanitary system budget since the sum of the costs of the individual drugs used is reached before reaching the definitive therapy, often represented by an anti-IL. This change translates into a series of indirect costs that must be added to the budget analysis of direct costs, already taken into account in literature.…”

Section: Discussionmentioning

confidence: 99%

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Margiotta

Michelucci

Panduri

et al. 2023

JEADV Clinical Practice

Self Cite

View full text Add to dashboard Cite

BackgroundMonoclonal antibodies (mAbs) directed against Tumor Necrosis Factor alpha (TNF‐α) and interleukin (IL)‐17 and 23 represent the ultimate therapeutic strategy in treating psoriasis patients, but scientific literature still does not provide conclusive results regarding the possible influence of previous biological therapies on real‐life therapeutic response.ObjectivesThe objective of our work was to investigate any putative difference in the achievement and maintenance of PASI 75, 90 and 100, as well as the probability to achieve absolute PASI≤1 and ≤ 3, between 305 bio‐naïve and bio‐experienced patients treated with anti‐IL mAbs.MethodsA comparison between previous biologic and clinical factors, including relative and absolute PASI, was carried out through chi square test. Survival curves for the achievement of PASI 75, 90 and 100 and their differences were evaluated, performing a multivariate analysis (Confidence Interval 95%; p‐value <0.0.5).ResultsPrevious biologic therapy resulted associated with a lower rate of PASI 75 (HR 1,339; p‐value 0,034), 90 (HR 1,365; p‐value 0,0031;) and 100 achievement (HR 1,596; p‐value 0,007).The survival curves showed how bio‐experienced patients were less likely to reach and maintain PASI 90 (naïve vs anti‐IL: p = 0.001; naïve vs anti‐TNF + anti‐IL: p <0.001) and PASI 100 (naïve vs anti‐TNF‐α: p = 0.014; naïve vs anti‐IL: p <0.001; naïve vs anti‐TNF‐α + anti‐IL: p < 0.001)]. Moreover, bio‐naïve patients showed a greater probability to achieve both absolute PASI≤3 and ≤ 1 (p<0.001)ConclusionsOur results represent a real‐life analysis on the impact of previous biologic therapy in the clinical efficacy of anti‐IL. Even if further studies with bigger samples are needed to extrapolate absolute considerations, we provided the first evidence on the burden of the bio‐naïve condition for a greater achievement of both PASI 90, 100 and the probability to achieve PASI≤1 and ≤ 3.This article is protected by copyright. All rights reserved.

show abstract

Section: Discussionmentioning

confidence: 99%

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Margiotta

Michelucci

Panduri

et al. 2023

JEADV Clinical Practice

Self Cite

View full text Add to dashboard Cite

show abstract

Treatment patterns and factors associated with discontinuation of monoclonal antibodies

Alkaabi,

Rabbani,

Rao

et al. 2024

SAGE Open Medicine

View full text Add to dashboard Cite

Background: Biological agents have revolutionized care in specialties such as oncology, immunology, infectious diseases, and genetic disorders, offering targeted actions on specific molecules or select immune cells. Monoclonal antibodies, known for their high specificity and precision, represent one of the most significant and rapidly expanding categories of these agents. Understanding the drug utilization patterns of monoclonal antibodies is crucial to ensure their optimal use, especially given their high cost and potential adverse effects. Methods: This analytical cross-sectional study was conducted in a secondary hospital in the United Arab Emirates. Patients of either gender receiving monoclonal antibodies at the study site were included. Treatment patterns, utilization, and factors associated with the discontinuation of monoclonal antibodies were assessed. Results: Hyperlipidemia (136, 39.1%) was the most common indication for monoclonal antibodies, followed by prophylaxis of respiratory syncytial virus infection in congenital heart disease (104, 29.9%) and osteoporosis (42, 12.1%). Evolocumab was the most commonly prescribed monoclonal antibody (135, 38.8%), followed by palivizumab (104, 29.9%), and dupilumab (38, 10.9%). The majority of monoclonal antibodies demonstrated a prescribed daily dose to defined daily dose ratio of 1.0, reflecting their appropriate utilization. One hundred twenty-nine patients (37.0%) discontinued their treatment during the study. Patient’s level of education (OR: 0.416, 95% CI: 0.183–0.943, p = 0.036), BMI (OR: 2.358, 95% CI: 1.164–4.777, p = 0.017), number of concomitant medications (OR: 2.457, 95% CI: 1.202–5.025, p = 0.014), and treatment duration (OR: 9.180, 95% CI: 4.909–17.165, p < 0.001) were identified as predictors of discontinuation of monoclonal antibodies. Conclusion: This study represents the first comprehensive investigation in the United Arab Emirates focused on treatment patterns, utilization, and discontinuation of monoclonal antibodies among the local population. Monoclonal antibodies were prescribed for the management of a wide range of clinical conditions. The study reports appropriate utilization of most monoclonal antibodies and identifies factors such as patient education level, BMI, concomitant medications, and treatment duration as independent predictors of monoclonal antibody treatment discontinuation.

show abstract

Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation

MANZO MARGIOTTA,

MICHELUCCI,

CAPALBO

et al. 2024

Ital J Dermatol Venereol

View full text Add to dashboard Cite

Family history of psoriasis: a novel protective factor for therapy switch in patients treated with Secukinumab or Ixekizumab

Cited by 3 publications

References 9 publications

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Bio‐experienced psoriasis patients treated with anti‐interleukin monoclonal antibodies are less likely to achieve PASI 90, PASI 100, PASI ≤ 1 and ≤3: Results from a cohort of 305 patients

Treatment patterns and factors associated with discontinuation of monoclonal antibodies

Efficacy of risankizumab after intra-class switching between anti IL-23 antagonists: a multi-center, retrospective, real-life observation

Contact Info

Product

Resources

About